T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status

REFERENCES

1. 1.↵
   2. Stupp R,
   3. Mason WP,
   4. van den Bent MJ, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96 doi:10.1056/NEJMoa043330 pmid:15758009

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Jain R,
   3. Poisson L,
   4. Narang J, et al

   . Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: a feasibility study. AJNR Am J Neuroradiol 2012;33:1343–48 doi:10.3174/ajnr.A2956 pmid:22422183

   Abstract/FREE Full Text
3. 3.↵
   2. Huang PH,
   3. Xu AM,
   4. White FM

   . Oncogenic EGFR signaling networks in glioma. Sci Signal 2009;2:re6 doi:10.1126/scisignal.287re6 pmid:19738203

   Abstract/FREE Full Text
4. 4.↵
   2. Mellinghoff IK,
   3. Wang MY,
   4. Vivanco I, et al

   . Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012–24 doi:10.1056/NEJMoa051918 pmid:16282176

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Gupta A,
   3. Young RJ,
   4. Shah AD, et al

   . Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification. Clin Neuroradiol 2015;25:143–50 doi:10.1007/s00062-014-0289-3 pmid:24474262

   CrossRefPubMed
6. 6.↵
   2. Kastenhuber ER,
   3. Huse JT,
   4. Berman SH, et al

   . Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathol 2014;127:747–59 doi:10.1007/s00401-013-1217-3 pmid:24292886

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Tykocinski ES,
   3. Grant RA,
   4. Kapoor GS, et al

   . Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol 2012;14:613–23 doi:10.1093/neuonc/nos073 pmid:22492960

   Abstract/FREE Full Text
8. 8.↵
   2. Essig M,
   3. Shiroishi MS,
   4. Nguyen TB, et al

   . Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol 2013;200:24–34 doi:10.2214/AJR.12.9543 pmid:23255738

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Cao Y,
   3. Sundgren PC,
   4. Tsien CI, et al

   . Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 2006;24:1228–35 doi:10.1200/JCO.2005.04.7233 pmid:16525177

   Abstract/FREE Full Text
10. 10.↵
    2. Shin KE,
    3. Ahn KJ,
    4. Choi HS, et al

    . DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma. Clin Radiol 2014;69:e264–72 doi:10.1016/j.crad.2014.01.016 pmid:24594379

    CrossRefPubMed
11. 11.↵
    2. Jung SC,
    3. Yeom JA,
    4. Kim JH, et al

    . Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 2014;35:1103–10 doi:10.3174/ajnr.A3825 pmid:24384119

    Abstract/FREE Full Text
12. 12.↵
    2. Tofts PS,
    3. Brix G,
    4. Buckley DL, et al

    . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32 doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S pmid:10508281

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Brennan CW,
    3. Verhaak RG,
    4. McKenna A, et al

    . The somatic genomic landscape of glioblastoma. Cell 2013;155:462–77 doi:10.1016/j.cell.2013.09.034 pmid:24120142

    CrossRefPubMedWeb of Science
14. 14.↵
    Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061–68 doi:10.1038/nature07385 pmid:18772890

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Heimberger AB,
    3. Hlatky R,
    4. Suki D, et al

    . Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462–66 doi:10.1158/1078-0432.CCR-04-1737 pmid:15746047

    Abstract/FREE Full Text
16. 16.↵
    2. Hirata A,
    3. Ogawa S,
    4. Kometani T, et al

    . ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554–60 pmid:11980649

    Abstract/FREE Full Text
17. 17.↵
    2. Ali MM,
    3. Janic B,
    4. Babajani-Feremi A, et al

    . Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One 2010;5:e8727 doi:10.1371/journal.pone.0008727 pmid:20090952

    CrossRefPubMed
18. 18.↵
    2. Katanasaka Y,
    3. Kodera Y,
    4. Kitamura Y, et al

    . Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer 2013;12:31 doi:10.1186/1476-4598-12-31 pmid:23617883

    CrossRefPubMed
19. 19.↵
    2. Inda MM,
    3. Bonavia R,
    4. Mukasa A, et al

    . Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731–45 doi:10.1101/gad.1890510 pmid:20713517

    Abstract/FREE Full Text
20. 20.↵
    2. Thomas AA,
    3. Brennan CW,
    4. DeAngelis LM, et al

    . Emerging therapies for glioblastoma. JAMA Neurol 2014;71:1437–44 doi:10.1001/jamaneurol.2014.1701 pmid:25244650

    CrossRefPubMed
21. 21.↵
    2. Xu LW,
    3. Chow KK,
    4. Lim M, et al

    . Current vaccine trials in glioblastoma: a review. J Immunol Res 2014;2014:796856 doi:10.1155/2014/796856 pmid:24804271

    CrossRefPubMed
22. 22.↵
    2. Mills SJ,
    3. Patankar TA,
    4. Haroon HA, et al

    . Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853–58 pmid:16611778

    Abstract/FREE Full Text
23. 23.↵
    2. Law M,
    3. Oh S,
    4. Babb JS, et al

    . Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 2006;238:658–67 doi:10.1148/radiol.2382042180 pmid:16396838

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Aronen HJ,
    3. Gazit IE,
    4. Louis DN, et al

    . Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51 doi:10.1148/radiology.191.1.8134596 pmid:8134596

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Ellika SK,
    3. Jain R,
    4. Patel SC, et al

    . Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. AJNR Am J Neuroradiol 2007;28:1981–87 doi:10.3174/ajnr.A0688 pmid:17893216

    Abstract/FREE Full Text
26. 26.↵
    2. Wetzel SG,
    3. Cha S,
    4. Johnson G, et al

    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803 doi:10.1148/radiol.2243011014 pmid:12202717

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Jain R,
    3. Gutierrez J,
    4. Narang J, et al

    . In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 2011;32:388–94 doi:10.3174/ajnr.A2280 pmid:21071537

    Abstract/FREE Full Text
28. 28.↵
    2. Fatterpekar GM,
    3. Galheigo D,
    4. Narayana A, et al

    . Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum—use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol 2012;198:19–26 doi:10.2214/AJR.11.7417 pmid:22194475

    CrossRefPubMed
29. 29.↵
    2. Young R,
    3. Babb J,
    4. Law M, et al

    . Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. J Magn Reson Imaging 2007;26:1053–63 doi:10.1002/jmri.21064 pmid:17896374

    CrossRefPubMed
30. 30.↵
    2. Gan HK,
    3. Kaye AH,
    4. Luwor RB

    . The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009;16:748–54 doi:10.1016/j.jocn.2008.12.005 pmid:19324552

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Jung SC,
    3. Choi SH,
    4. Yeom JA, et al

    . Cerebral blood volume analysis in glioblastomas using dynamic susceptibility contrast-enhanced perfusion MRI: a comparison of manual and semiautomatic segmentation methods. PLoS One 2013;8:e69323 doi:10.1371/journal.pone.0069323 pmid:23950891

    CrossRefPubMed